Episurf Medical (NASDAQ: EPIS B) today announces that the scientific abstract “Clinical results of an individualized mini-metal implant for focal cartilage lesions in the knee” by Ass. Prof. Karl Eriksson et al. has been accepted for presentation at the annual congress of the Australian Knee Society (AKS). The congress will take place in Broome, Australia on October 11-13, 2018. The abstract focuses on interim results from a European multicenter study with the Episealer® knee implant. The results will be presented by Ass. Prof. Karl Eriksson from Stockholm South General Hospital, Sweden.
“We are happy that the clinical results from use of the Episealer implant will be presented at this meeting. The results show high patient reported scores and a low early revision rate and this is exactly what we want to achieve. Our customers attest to the treatment gap and all proofs of successful treatment of this patient group are highly interesting. We are currently reviewing the regulatory pathway for a market entrance in Australia and it is definitely a market for us on mid- to long-term.” says Pål Ryfors, CEO Episurf Medical.
For more information, please contact:
Pål Ryfors, CEO, Episurf Medical
Tel:+46 (0) 709 62 36 69
About Episurf Medical
Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and personalised treatment alternatives. Episurf Medical’s Episealer® personalised implants and Epiguide® surgical drill guides are developed for treating localized cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com.